Robert F. Kennedy Jr. has been the single most-watched federal voice on peptides since taking over HHS. The throughline has been a more permissive posture toward research peptides and compounding, paired with skepticism of GLP-1s as a public-health response to obesity.
The most consequential reporting came from ProPublica: RFK Jr. is preparing to reverse the FDA's 2023 effective ban on 19 injectable peptides from compounding pharmacies, prompting public pushback from former FDA officials. Smaller signals followed — softer language in PCAC meetings, slowed enforcement on certain compounding actions, and reframed messaging around dietary supplements and peptide therapy clinics.
The FDA's April 30 proposal to exclude branded GLP-1 actives from the 503B bulks list cuts the other way. Stories here cover the policy moves, the public statements, and the gap between the two.
Pharmacy Times hosted a CME-eligible virtual symposium May 19 (1:00-2:30 PM EDT) framing the post-RFK Jr. peptide moment for hospital and retail pharmacists. The agenda crossed the wellness-clinic side (BPC-157, TB-500, CJC-1295, GHK-Cu after the April 22 503A Category-2 removal) with the FDA-approved peptide side (semaglutide, tirzepatide, liraglutide, navepegritide, paltusotine) and walked attendees through the July 23-24 PCAC vote calculus and patient counseling around compounded GLP-1 risk.
STAT News published an April 29 First Opinion piece arguing that the FDA's pending peptide reclassifications — driven by HHS Secretary RFK Jr.'s public enthusiasm for compounds like BPC-157 and GHK-Cu — risk reopening access to inadequately-tested compounds. The op-ed highlights specific safety concerns flagged in the FDA's original 2023 Category 2 designations: immunogenicity, impurities, and the absence of meaningful human clinical data. The piece is positioned as scientific-community pushback ahead of the July 23-24 PCAC meeting that will rule on seven peptides.
FormBlends, a telehealth platform focused on medically supervised GLP-1 and peptide therapy, released its 2026 State of Peptides and GLP-1 Regulation Report on April 28. The report maps how RFK Jr.'s HHS, the FDA Center for Drug Evaluation and Research, and the next-generation obesity pipeline from Eli Lilly, Novo Nordisk, Boehringer Ingelheim, and Roche are reshaping legal access for weight management, metabolic health, and peptide therapy through the end of the decade. The report follows the April 22 formal removal of 12 peptides from FDA Category 2 and previews the July 23-24 PCAC meeting.
Yahoo published an April 23 consumer-facing explainer titled "Wait, So Are Peptides Legal Now?" — the most widely-circulated translation of last week's FDA Category 2 removal for a mainstream audience. The piece walks through which 12 peptides were removed from the restricted list, what the July 23-24 PCAC meeting will actually decide, the distinction between reclassification and FDA approval, and the practical implications for compounding pharmacies and patients. The article marks the peptide-regulation story's transition into general consumer awareness.
Effective April 22, BPC-157, TB-500, Semax, Epitalon, MOTS-c and seven other peptides were formally removed from the FDA's 503A Category 2 significant-safety-concerns list after original nominators withdrew submissions. The FDA Pharmacy Compounding Advisory Committee will meet July 23-24 to decide whether to add these peptides to the 503A bulks list, which would restore legal compounding under prescription.
A Bloomberg opinion piece published April 21 argues that the FDA's planned July 23-24 PCAC review of seven peptides (BPC-157, MOTS-c, KPV, among others) and RFK Jr.'s broader push to reclassify 14 of 19 Category 2 peptides doesn't give consumers the evidence-based safety and efficacy data they need. The piece frames the ongoing compounding debate as a consumer-protection gap that clinical trial evidence — not political reclassification — should fill.
CNBC analysis frames Hims & Hers Health as the biggest direct-to-consumer beneficiary of the FDA's July PCAC meeting. Hims acquired a California peptide manufacturing facility in 2025 and can convert its GLP-1 compounding infrastructure to peptide production. The stock closed up 11.07% on April 16 after the FDA announcement; Bank of America raised its price target from $21 to $25, citing the platform's conversion potential.
A BioCentury analysis argues the FDA's April 16 decision to convene a July Pharmacy Compounding Advisory Committee meeting on 12 previously restricted peptides reflects HHS Secretary RFK Jr.'s enthusiasm more than scientific evidence. The outlet warns that most of the peptides under review — for conditions spanning ulcerative colitis, wound healing, obesity, insomnia, and neurological disorders — lack robust clinical safety or efficacy data, and that ideology is increasingly shaping agency decisions.
STAT News analysis of the composition of the July 23-24 Pharmacy Compounding Advisory Committee suggests panelists are likely to vote in favor of broader peptide access. The panel will review BPC-157 (ulcerative colitis), KPV (wound healing), TB-500, MOTS-c, emideltide, semax, and epitalon — largely aligning with RFK Jr.'s February 2026 pledge to move 14 restricted peptides back to Category 1.
The FDA announced it will convene the Pharmacy Compounding Advisory Committee on July 23-24 to evaluate whether seven or more peptides — including BPC-157, TB-500, and other popular wellness peptides — should be added to the list of substances eligible for pharmacy compounding. The announcement follows HHS Secretary RFK Jr.'s February pledge to reclassify 14 restricted peptides.
Scientific American reports that the FDA's decision to convene an expert advisory panel — rather than unilaterally reclassifying peptides — signals a more cautious approach than RFK Jr.'s original February pledge suggested. The panel will weigh limited safety data against surging consumer demand and a growing black market for unregulated peptide products.
ProPublica published a major investigation into the FDA's planned reversal on 19 restricted peptides, warning that reclassification under HHS Secretary RFK Jr. could expose consumers to inadequately tested drugs. The Alliance for Pharmacy Compounding acknowledged it knows little about the safety of individual peptides being sold to the public.
In-depth feature on peptide mania in wellness culture. HHS Secretary RFK Jr. wants to make unapproved wellness peptides more available to the public. The piece distinguishes FDA-regulated peptides from the largely untested 'wellness' peptides embraced by those mistrustful of mainstream medicine.
Three former officials maintain the 2023 decision to deem 19 peptides unsafe for compounding was grounded in documented safety concerns, countering Kennedy's claims on Joe Rogan.
ProPublica reveals the potential reversal of the FDA's 2023 ban on 19 compounded peptides. Three former FDA officials, including former acting commissioner Janet Woodcock, say RFK Jr. mischaracterized their work and that documented safety concerns supported the ban.
Digital health companies are betting on peptides as the next big wellness category. They're banking on HHS Secretary RFK Jr. getting the FDA to lift restrictions on certain peptides.
Federal regulators are moving toward restoring legal access to injectable peptides barred from pharmacy compounding in 2023, which could redirect patients from unregulated online sellers to regulated pharmacy channels.
The FDA is moving to allow compounding pharmacies to produce 14+ injectable peptides banned in 2023. Health Secretary RFK Jr. publicly backed the reversal, while top FDA leaders reportedly have reservations about politically-driven decisions.